<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 1997
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from _________________to ___________________
Commission file number 1-10538
GAMMA BIOLOGICALS, INC.
---------------------------------------------------------
(Exact name of registrant as specified in its charter)
Texas 74-1668436
- ---------------------------------- ---------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
3700 Mangum Road, Houston, Texas 77092
---------------------------------------------------------
(Address of principal executive offices) (Zip code)
(713) 681-8481
---------------------------------------------------------
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes [X] No [ ]
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
At November 13, 1997: 4,605,111 shares
<PAGE>
PART I. FINANCIAL INFORMATION
GAMMA BIOLOGICALS, INC.
Consolidated Balance Sheets
ASSETS SEPTEMBER 30, 1997 MARCH 31, 1997
------------------ --------------
(UNAUDITED)
CURRENT ASSETS:
Cash and cash equivalents.............. $ 3,065,683 $ 3,618,970
Short-term investments................. 100,000 100,000
Receivables - net of allowance for
doubtful accounts of $128,811 and
$105,505, respectively............... 3,862,724 3,524,585
Inventories............................ 3,781,476 3,658,642
Prepaid expenses....................... 603,165 515,660
Deferred taxes......................... 81,300 73,400
----------- ----------
Total current assets................... 11,494,348 11,491,257
----------- ----------
PROPERTY - at cost, net of accumulated
depreciation and amortization of
$6,219,744 and $6,241,338,
respectively.......................... 6,365,406 5,994,374
CASH VALUE OF LIFE INSURANCE............ 1,904,230 1,858,672
EXCESS OF COST OVER NET ASSETS
ACQUIRED-NET........................... 124,166 139,686
OTHER ASSETS............................ 602,631 385,538
----------- ----------
TOTAL.................................. $20,490,781 $19,869,527
=========== ==========
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Current portion of long-term obligations $ 114,389 $ 127,761
Accounts payable - trade............... 847,777 786,214
Dividends payable...................... 115,114 115,077
Accrued salaries and other expenses.... 251,594 294,748
----------- ----------
Total current liabilities............ 1,328,874 1,323,800
----------- ----------
LONG-TERM OBLIGATIONS................... 501,372 345,120
----------- ----------
DEFERRED TAXES.......................... 589,800 535,700
----------- ----------
SHAREHOLDERS' EQUITY.................... 18,070,735 17,664,907
----------- ----------
TOTAL.................................. $20,490,781 $19,869,527
=========== ==========
See notes to unaudited consolidated financial statements.
2
<PAGE>
GAMMA BIOLOGICALS, INC.
Statements of Consolidated Income
(Unaudited)
<TABLE>
<CAPTION>
THREE MONTHS ENDED SIX MONTHS ENDED
---------------------------------------------------
SEPTEMBER 30, SEPTEMBER 30,
------------------------ ------------------------
1997 1996 1997 1996
--------- ---------- ---------- ----------
<S> <C> <C> <C> <C>
NET SALES............................... $4,611,500 $4,176,869 $9,439,492 $8,388,905
COST OF SALES........................... 2,024,495 1,731,526 4,189,900 3,716,118
----------- ----------- ---------- ----------
GROSS MARGIN............................ 2,587,005 2,445,343 5,249,592 4,672,787
----------- ----------- ---------- ----------
OPERATING EXPENSES:
Selling............................... 1,127,241 888,145 2,213,170 1,751,511
General and administrative............ 647,458 552,063 1,235,583 1,085,292
Shipping and warehouse................ 180,526 184,186 370,900 353,004
Research and development.............. 344,874 365,734 689,443 695,650
----------- ----------- ---------- ----------
Total operating expense............ 2,300,099 1,990,128 4,509,096 3,885,457
----------- ----------- ---------- ----------
OPERATING INCOME........................ 286,906 455,215 740,496 787,330
----------- ----------- ---------- ----------
UNUSUAL ITEM:
Adjustment to Carrying Value of
Facility............................. 150,000 150,000
----------- ----------- ---------- ----------
OTHER INCOME (EXPENSE):
Interest income....................... 64,982 53,788 125,645 101,594
Interest expense...................... (7,599) (10,700) (18,882) (22,112)
Other - net........................... (9,504) 3,417 (18,904) (562)
----------- ----------- ---------- ----------
Other income - net................. 47,879 46,505 87,859 78,920
----------- ----------- ---------- ----------
INCOME BEFORE INCOME TAXES.............. 484,785 501,720 978,355 866,250
INCOME TAXES............................ 163,782 169,400 348,346 313,500
----------- ----------- ---------- ----------
NET INCOME.............................. $ 321,003 $ 332,320 $ 630,009 $ 552,750
=========== =========== ========== ==========
Weighted average number of common and
common equivalent shares outstanding. 4,713,549 4,574,656 4,713,470 4,574,058
----------- ----------- ---------- ----------
Net income per common and common
equivalent share..................... $.07 $.07 $.14 $.12
=========== =========== ========== ==========
</TABLE>
See notes to unaudited consolidated financial statements.
3
<PAGE>
GAMMA BIOLOGICALS, INC.
Statements of Consolidated Changes in Shareholders' Equity
(Unaudited)
<TABLE>
<CAPTION>
SIX MONTHS ENDED
--------------------------
SEPTEMBER 30,
--------------------------
1997 1996
-------------------------- --------------------------
SHARES AMOUNT SHARES AMOUNT
----------- ------------- ----------- -------------
<S> <C> <C> <C> <C>
COMMON STOCK
Balance, beginning of period.......... 4,762,615 $ 476,261 4,711,365 $ 471,136
Acquisition of wholly-owned subsidiary 50,000 5,000
Exercise of stock options............. 500 50 1,000 100
-------------------------------------------------------
Balance, end of period................ 4,763,115 476,311 4,762,365 476,236
-------------------------------------------------------
CAPITAL IN EXCESS OF PAR
Balance, beginning of period.......... 13,674,209 13,512,836
Acquisition of wholly-owned subsidiary 157,500
Exercise of stock options............. 1,700 2,710
-------------------------------------------------------
Balance, end of period................ 13,675,909 13,673,046
-------------------------------------------------------
RETAINED EARNINGS
Balance, beginning of period.......... 4,644,801 3,988,022
Net income............................ 630,009 552,750
Dividends declared.................... (230,190) (228,893)
-------------------------------------------------------
Balance, end of period................ 5,044,620 4,311,879
-------------------------------------------------------
TRANSLATION ADJUSTMENTS
Balance, beginning of period.......... (10,456)
Current period translation adjustments 4,259
-------------------------------------------------------
Balance, end of period................ (6,197)
-------------------------------------------------------
TREASURY STOCK.......................... (159,563) (1,119,908) (159,563) (1,119,908)
-------------------------------------------------------
TOTAL SHAREHOLDERS' EQUITY.............. 4,603,552 $ 18,070,735 4,602,802 $ 17,341,253
=======================================================
</TABLE>
See notes to unaudited consolidated financial statements.
4
<PAGE>
GAMMA BIOLOGICALS, INC.
Statements of Consolidated Cash Flows
(Unaudited)
SIX MONTHS ENDED
-----------------------------
SEPTEMBER 30,
-----------------------------
1997 1996
-------------- -------------
[INCREASE (DECREASE) IN CASH]
Cash flows from operating activities:
Cash received from customers.......... $ 9,220,247 $ 9,048,041
Interest received..................... 123,201 103,792
Cash paid to suppliers and employees.. (8,642,356) (7,754,624)
Interest paid......................... (18,877) (22,112)
Income taxes paid..................... (300,457) (243,000)
------------ -----------
Net cash provided by operating
activities........................... 381,758 1,132,097
------------ -----------
Cash flows from investing activities:
Property additions.................... (728,882) (895,738)
Increase in cash value of life
insurance............................ (45,558) (129,891)
Proceeds from investments............. 2,443 2,343
Investment in subsidiary.............. 142,659
Proceeds from assets disposed of...... 150,000 49
------------ -----------
Net cash used in investing activities. (621,997) (880,578)
------------ -----------
Cash flows from financing activities:
Payments on long-term obligations..... (81,800) (55,022)
Exercise of stock options............. 1,750 2,811
Dividends paid........................ (230,153) (227,618)
------------ -----------
Net cash used in financing activities. (310,203) (279,829)
------------ -----------
Effect of exchange rate fluctuation
on cash.............................. (2,845)
Net decrease in cash.................... (553,287) (28,310)
Cash and cash equivalents at beginning
of period.............................. 3,618,970 3,724,379
------------ -----------
Cash and cash equivalents at end of
period................................. $ 3,065,683 $ 3,696,069
============ ===========
5
<PAGE>
GAMMA BIOLOGICALS, INC.
Statements of Consolidated Cash Flows
(Unaudited)
Reconciliation of Net Income to
Net Cash Provided by Operating Activities
SIX MONTHS ENDED
-------------------------
SEPTEMBER 30,
-------------------------
1997 1996
----------- ------------
Net Income $ 630,009 $ 552,750
Adjustments to reconcile net income to
cash provided by operating activities:
Depreciation........................ 496,050 359,717
Amortization of goodwill............ 15,520
Loss on sale of fixed assets........ 5,497 2,863
(Increase) decrease in accounts
receivable......................... (187,388) 608,359
(Gain) loss on sale of investments.. (2,444) 2,198
Increase in inventory............... (112,731) (548,645)
Increase in prepaid expenses........ (291,943) (7,583)
(Increase) decrease in other assets. (217,094) 25,281
Increase in accounts payable........ 40,082 160,934
Increase (decrease) in accrued
salaries and other expenses........ 6,200 (23,777)
--------- --------
Net Cash Provided by
Operating Activities.................. $ 381,758 $1,132,097
========= =========
Supplemental Schedule of Non-Cash Investing and Financing Activities:
In March 1996, the company outsourced the assembly of plastic droppers and
SegmentSamplers(TM). As a result, inventory of component parts totaling $282,886
was transferred to outside vendors and a corresponding receivable due from the
vendors was recorded. This receivable is being reduced as assembled parts are
delivered, with the cost of components deducted from the vendors' selling price.
To date, additional inventory of $105,000 was transferred to outside vendors and
the outstanding receivable balance at September 30, 1997 was $9,778 .
The company purchased 100% of the outstanding shares of Gamma Biologicals, B.V.,
effective September 30, 1996, for 50,000 shares of common stock. In conjunction
with the acquisition, assets of $336,000 (including $143,000 cash) were
received, and liabilities of $313,000 were assumed.
In June 1997, the company entered into a capital lease agreement for
approximately $700,000 for the design, manufacture, and installation of a
special filling and heat-sealing machine for the ReACT strips. As of September
30, 1997, $230,500 has been funded. The capital lease bears interest at 7% and
payments will be due quarterly over five years following the installation of the
equipment in January 1998.
See notes to unaudited consolidated financial statements.
6
<PAGE>
GAMMA BIOLOGICALS, INC.
Notes to Consolidated Financial Statements
(Unaudited)
1. Reconciliation of statutory rate with effective United States income tax
rate:
THREE MONTHS ENDED SIX MONTHS ENDED
------------------ -----------------
SEPTEMBER 30, SEPTEMBER 30,
------------------ -----------------
1997 1996 1997 1996
------ ----- ------ ----
Statutory rate...................... 34.0% 34.0% 34.0% 34.0%
Increase (decrease) resulting from:
Exempt export earnings............. (2.0) (2.3) (2.0) (2.7)
Life insurance premiums............ 1.2 .5 1.2 .6
Research and development credit.... (3.7) (5.2)
Valuation of temporary differences. 2.0 .9 3.6 3.5
Other-net.......................... 2.2 .7 1.3 .8
------- ------ ------ ------
Effective tax rate.................. 33.7% 33.8% 32.9% 36.2%
======= ====== ====== ======
Significant components of the company's deferred tax assets (liabilities) are
as follows:
SEPTEMBER 30, MARCH 31,
1997 1997
----------- ----------
Allowance for bad debts................ $ 43,800 $ 35,900
Inventory costs capitalized............ 37,500 37,500
--------- ---------
Net current deferred tax asset...... 81,300 73,400
--------- ---------
Difference between book and tax basis
of property, plant and equipment...... (588,300) (523,900)
Other.................................. (1,500) (11,800)
--------- ---------
Net noncurrent deferred
tax liability...................... (589,800) (535,700)
--------- ---------
Net deferred tax liability............. $ (508,500) $ (462,300)
========= =========
2. Net income per common and common equivalent share is computed using weighted
average number of shares and dilutive equivalent shares outstanding during
each period. The weighted average number of shares for the three month period
ended September 30, was 4,713,549 in 1997 and 4,574,656 in 1996; for the six
month period then ended, 4,713,470 in 1997 and 4,574,058 in 1996.
7
<PAGE>
3. Inventories are valued at the lower of cost (principally FIFO) or market
value, as follows:
SEPTEMBER 30, 1997 MARCH 31, 1997
------------------ --------------
Raw materials......................... $1,043,271 $1,144,949
Products in Process................... 326,067 432,357
Finished products..................... 1,591,166 1,319,605
Supplies.............................. 820,972 761,731
--------- ---------
Total............................. $3,781,476 $3,658,642
========= =========
4. In the opinion of management, the unaudited consolidated condensed financial
statements for Gamma Biologicals, Inc. (the "company") include all
adjustments (consisting solely of normal recurring adjustments) necessary for
a fair presentation of the financial position of the company as of September
30, 1997, the results of operations of the three and six month periods ended
September 30, 1997 and 1996 and cash flows for the six month periods ended
September 30, 1997 and 1996. Although management believes the disclosures in
these financial statements are adequate to make the information presented not
misleading, certain information and footnote disclosures normally included in
annual financial statements prepared in accordance with generally accepted
accounting principles have been condensed or omitted pursuant to the rules
and regulations of the Securities and Exchange Commission. The results of
operations for the period ended September 30, 1997 are not necessarily
indicative of the results to be expected for the full year.
5. LONG-TERM OBLIGATIONS
Long-term obligations consist of:
SEPTEMBER 30, 1997 MARCH 31, 1997
------------------ --------------
Mortgage note, due monthly through
2000................................. $ 309,538 $ 353,485
Note payable-foreign, due
semiannually through 2000............ 75,701 119,396
Other obligations..................... 230,522
--------- ---------
615,761 472,881
Less current portion.............. 114,389 127,761
--------- ---------
Total long-term obligations........... $ 501,372 $ 345,120
========= =========
The mortgage note bears interest at the bank's base rate, but not less than 7%
nor more than 13%. At September 30, 1997, the note bore interest at 9.5%. The
mortgage note is collateralized by a first lien on the company's land and
building. The foreign note payable bears interest at 7%.
In June 1997, the company entered into a capital lease agreement for
approximately $700,000 for the design, manufacture, and installation of a
special filling and heat-sealing machine for the ReACT strips. As of
September 30, 1997, $230,500 has been funded. The interest rate varies
dependent upon the amount funded. At September 30, 1997, the note bore
interest at 7%.
8
<PAGE>
6. ACQUISITION OF WHOLLY-OWNED SUBSIDIARY
Effective September 30, 1996, the company acquired 100% of the outstanding
shares of its distributor in the Netherlands, Gamma Biologicals, B.V.
Consideration for the acquisition was 50,000 shares of Gamma common stock,
valued at $3.25 per share, the market price on the effective date. The
acquisition has been accounted for using the purchase method of accounting,
and accordingly, the purchase price has been allocated to the assets purchased
and the liabilities assumed based upon the fair values at the date of
acquisition. The excess of the purchase price over the fair values of the net
assets acquired was $155,207 and has been recorded as goodwill, which is being
amortized over five years.
Gamma Biologicals, B.V. was formed in November 1993 to market Gamma products
and certain noncompeting product lines in the Netherlands. Subsequent to the
acquisition, the subsidiary will continue to sell directly in the Netherlands,
as well as serve as a European distribution center.
7. MINOR DAMAGE TO FACILITY
On September 11, 1997, the company's manufacturing facility in Houston, Texas
sustained minor damage from a fire that occurred while the building was
unoccupied. The company was open for business on September 12, and most
manufacturing activities resumed within seven days. Reconstruction of all
affected areas should be completed by December 31, 1997.
The company maintains insurance for both property damage and business
interruption. The policy providing the coverages is subject to deductibles of
$5,000 each for property damage and business interruption. As of November 13,
1997, the insurance carrier has advanced $1,000,000 to cover estimated costs
to clean up, repair or replace damaged property. The total cost to restore
the facility is estimated at $1,500,000.
Insurance recoveries for property damage associated with events of this type
require the recognition of a new cost basis for the rebuilt or replaced
assets. As a result, the company has recognized in its statement of income
for the period ended September 30, 1997, an adjustment to the carrying value
of the facility to the extent of recoveries received. Total spending to
restore the facility was approximately $150,000 during the period.
9
<PAGE>
8. OPERATIONS BY GEOGRAPHIC AREA
The company operates within one dominant segment - the manufacture and sale of
blood bank and diagnostic products - and has no customer which accounts for
10% or more of its total sales. During the three and six month periods ended
September 30, 1997 the company operated in two geographic areas, the United
States and Europe. Prior to the September 30, 1996 acquisition of Gamma
Biologicals, B.V., the company operated in one geographic area, the United
States, from which it sold to numerous countries.
THREE MONTHS ENDED SIX MONTHS ENDED
------------------ -----------------
SEPTEMBER 30, SEPTEMBER 30,
------------------ -----------------
1997 1996 1997 1996
-------- -------- ------- --------
(in thousands)
Net sales to unaffiliated customers:
United States....................... $3,082 $ 2,842 $6,164 $ 5,919
Europe.............................. 617 368 1,259 758
Pacific Region...................... 287 391 647 708
Mexico, Central and South America... 425 402 814 642
Middle East......................... 142 124 439 266
Other............................... 59 50 116 95
----------------------------------
Total.............................. $4,612 $ 4,177 $9,439 $ 8,388
==================================
Export sales from United States to
unaffiliated customers:
Europe.............................. $ 349 $ 368 $ 707 $ 758
Pacific Region...................... 287 391 642 708
Mexico, Central and South America... 425 402 814 642
Middle East......................... 142 124 439 266
Other............................... 59 50 116 95
----------------------------------
Total.............................. $1,262 $ 1,335 $2,718 $ 2,469
==================================
Sales between geographic areas:
United States to Europe......... $ 157 $ 283
----------------------------------
Income before income taxes:
United States....................... $ 468 $ 502 $ 877 $ 866
Europe.............................. 17 101
----------------------------------
Total.............................. $ 485 $ 502 $ 978 $ 866
==================================
9/30/97 3/31/97
-------- --------
Identifiable assets:
United States....................... $ 17,986 $ 17,468
Europe.............................. 386 318
Corporate........................... 2,119 2,083
-----------------------------
Total.............................. $ 20,491 $ 19,869
=============================
10
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
The following is a discussion of the company's financial condition, results of
operations, capital resources and liquidity. This discussion and analysis
should be read in conjunction with the Consolidated Financial Statements of the
company and the notes thereto. Management's review includes certain forward-
looking statements reflecting the company's expectations in the near future;
however, many factors which may affect the actual results, especially market
conditions and changing regulations, are difficult to predict. Accordingly,
there is no assurance that the company's expectations will be realized.
RESULTS OF OPERATIONS
THREE MONTHS ENDED SEPTEMBER 30, 1997
Revenues increased 10% for the three months ended September 30, 1997 compared
with the same period in 1996 with international sales accounting for 33% of
total sales and domestic sales increasing 8%. On the domestic front, increased
sales of RQC products and a significant price increase for one third-party
product late in fiscal 1996 has tripled the revenue for this product and offset
declines in other product lines due to certain contracts awarded to competitors
and the phase out of products at the end of their lifecycles. International
sales rose 15% overall. European sales rose 68%, including the increased
contribution of Gamma Biologicals, B.V., the company's subsidiary in the
Netherlands acquired September 30, 1996. The Middle East, principally Saudi
Arabia, also added to second quarter revenues. The measurable growth in
international sales reflects the company's focus on globalization to overcome
the competitive pressures in the domestic market. In late September 1997 the
FDA approved the company's 510K application to market the Gamma-ReACT(TM) Test
System. The U. S. Patent Office also issued the first of three patents that
were applied for regarding ReACT adherence technology. Preliminary marketing
information indicates that the ReACT system could contribute over $3,000,000 of
revenues during the first full year of sales.
Gross margin as a percentage of sales declined to 56% in 1997 from 58% in
1996. The margin was negatively affected by the higher sales volume and lower
gross margin generated by the third-party product mentioned above.
Selling expense increased 27% for the quarter; 36% of the increase was due to
activity at Gamma Biologicals, B.V. The increase also reflects higher
international commissions, more frequent international travel and the addition
domestically of one salesperson. General and administrative expenses rose 17%
over the prior year mainly due to increased depreciation and amortization
related to the computer upgrade implemented in the latter part of fiscal 1996
and increased investor relations expense. Shipping and warehouse expenses
remained at 4% of sales.
Research and development expenses declined 6% over the same quarter last year
due to reduced expenditures for the Gamma-ReACT Test System and other programs.
11
<PAGE>
The company's manufacturing facility sustained minor damage from a fire on
September 11, 1997. As a result, the company has recognized in its statement of
income for the period ended September 30, 1997, an adjustment to the carrying
value of the facility to the extent of recoveries received. Total spending to
restore the facility was approximately $150,000 during the period.
The contribution of interest and other income and the provision for income
taxes remained relatively constant between the periods.
In February 1997, the FASB issued SFAS No. 128, "Earnings Per Share." SFAS 128
establishes standards for computing and presenting earnings per share ("EPS")
and applies to entities with publicly held common stock or potential common
stock. This statement simplifies the standards for computing EPS previously
found in Accounting Principles Board Opinion No. 15, "Earnings Per Share," and
makes them comparable to international EPS standards. This statement is
effective for financial statements issued for periods ending after December 15,
1997, including interim periods; earlier application is not permitted. This
statement requires restatement of all prior-period EPS data presented.
Considering the guidelines as prescribed by SFAS 128, management believes that
the adoption of this statement will not have a material effect on EPS and thus
pro forma EPS, as suggested for all interim and annual periods prior to required
adoption, have been omitted.
In June 1997, the FASB issued SFAS No. 130, "Reporting Comprehensive Income",
and SFAS No. 131, "Disclosures About Segments of an Enterprise and Related
Information". SFAS No. 130 establishes standards for reporting and displaying of
comprehensive income and its components. SFAS No. 131 establishes standards for
the way that public business enterprises report information about operating
segments and related information in interim and annual financial statements.
SFAS No. 130 and 131 are effective for periods beginning after December 15,
1997. These two statements will not have any effect on the company's 1997
financial statements, however, management is evaluating what, if any, additional
disclosures may be required when these two statements are implemented.
SIX MONTHS ENDED SEPTEMBER 30, 1997
Net income for the six months ended September 30, 1997 rose 14% over the prior
period. A 13% increase in revenues was offset by a 16% increase in operating
expenses as outlined above for the three month period ended September 30, 1997.
In addition, an adjustment to the carrying value of the facility as stated above
resulted in increased pretax earnings.
LIQUIDITY AND CAPITAL RESOURCES
Net cash flows decreased approximately $525,000 during the six month period
ended September 30, 1997 compared with the same period in 1996. Operating cash
flows shrunk significantly due to the following factors. The accounts
receivable turn has declined to 72 days from 65 days for the same period in
1996, or approximately $800,000, due to the heavy emphasis on international
sales that typically have longer payment terms. In the first quarter, a fee of
$200,000 was paid to acquire a nonexclusive license from the owner of a patent
covering
12
<PAGE>
certain technology utilized in the ReACT test strips in certain European
countries. Management believes, however, that operating cash flows will be
sufficient to meet future operating needs.
Approximately $1,000,000 has been committed for 500 additional ReACT
centrifuges and incubators to be delivered in the third and fourth quarters. In
June 1997, we placed an order for customized equipment to automate the filling,
sealing and labeling of ReACT test strips, with delivery scheduled for January
1998. The estimated cost of this equipment is approximately $700,000; the
company has entered into a lease agreement to finance the equipment purchase.
The company has contracted with a medical equipment manufacturer to provide
automated dispensing and reading devices for use with the ReACT Test System.
The contract commits the company to purchase 50 dispensers and/or readers during
the first three years following FDA approval to market the devices in the U.S.
Our estimated cost should range between $650,000 and $1,700,000, depending on
product mix. These devices should be available for sale outside the U.S. by
mid-1998.
The company's existing capital resources, consisting of $3,160,000 in cash and
short-term investments and a $1,500,000 revolving credit line, should be
sufficient to support planned product development and capital improvements
during the next 12 months.
RECENT SALES OF EXEMPT SECURITIES
In June 1997, the company granted Cyn Del & Co., Inc. a warrant to purchase
100,000 shares of the company's common stock at an exercise price of $5.00 per
share (the "Warrant") pursuant to Section 4(2) of the Securities Act of 1933.
The Warrant is exercisable by Cyn Del & Co., Inc. at any time prior to June 19,
2002. The company granted the Warrant as partial consideration for consulting
services to be provided to the company's board of directors by Cyn Del & Co.,
Inc.
13
<PAGE>
PART II - OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits, Part II
(27) Article 5 Financial Data Schedule
(b) Reports on Form 8-K - None
14
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed in its behalf by the
undersigned thereunto duly authorized.
GAMMA BIOLOGICALS, INC.
November 13, 1997 By:/s/ David E. Hatcher
---------------------------------
David E. Hatcher
President
(Chief Executive Officer)
November 13, 1997 By:/s/ Margaret J. O'Bannion
--------------------------------
Margaret J. O'Bannion
Vice President - Finance
(Chief Financial Officer)
15
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM CONSOLIDATED
BALANCE SHEETS AND STATEMENTS OF CONSOLIDATED INCOME AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> MAR-31-1998
<PERIOD-END> SEP-30-1997
<CASH> 3,065,683
<SECURITIES> 100,000
<RECEIVABLES> 3,991,535
<ALLOWANCES> 128,811
<INVENTORY> 3,781,476
<CURRENT-ASSETS> 11,494,348
<PP&E> 12,583,150
<DEPRECIATION> 6,219,744
<TOTAL-ASSETS> 20,490,781
<CURRENT-LIABILITIES> 1,328,874
<BONDS> 501,372
0
0
<COMMON> 476,311
<OTHER-SE> 17,594,424
<TOTAL-LIABILITY-AND-EQUITY> 20,490,781
<SALES> 9,439,492
<TOTAL-REVENUES> 9,439,492
<CGS> 4,189,900
<TOTAL-COSTS> 3,273,513
<OTHER-EXPENSES> 1,203,726
<LOSS-PROVISION> 31,857
<INTEREST-EXPENSE> 18,882
<INCOME-PRETAX> 978,355
<INCOME-TAX> 348,346
<INCOME-CONTINUING> 630,009
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 630,009
<EPS-PRIMARY> .14
<EPS-DILUTED> .14
</TABLE>
